人体恶性实体瘤TIL增殖力、表型和杀伤力研究

在建立高活力肿瘤浸润淋巴细胞（ＴＩＬ）分离培养方法的基础上，对８３例恶性实体瘤ＴＩＬ的细胞增殖动力学、部份ＴＩＬ表型与杀伤力等作了较为系统的研究。结果提示，本实验室所建立分离培养的ＴＩＬ增殖能力较强且稳定，有６５％的增殖倍数大于１０００倍；３Ｈ－ＴｄＲ掺入高峰在培养的第４５～７５天；对其自身的原代肿瘤细胞杀伤力可以维持至５６天以上；对５６份经ｒＩＬ２诱导的ＴＩＬ（培养时间１７±５．２天）表型分析：ＣＤ３８０±２１％，ＣＤ４３７±２１％，ＣＤ８４４±１８％，ＨＬＡＤＲ６９±２４％，与ｒＩＬ２诱导前比较，ＣＤ３、ＣＤ４、ＣＤ８和ＨＬＡＤＲ均增多，尤以ＣＤ３与ＣＤ８表型增多明显。     

异体角膜刺激引起的人外周血T细胞及其亚群CD25分子表达

目的：观察异体角膜体外对人外周血T细胞及其亚群CD25分子表达的影响。方法： 异体角膜与外周血淋巴细胞体外共同培养后，进行单克隆抗体标记和流式细胞分析。结果： 对照组T细胞CD25表达为25.2％；受角膜或沸波醇酯（PDB）激活后T细胞CD25表达分别为56.8％和80.9％；受角膜和沸波醇酯共同激活后T细胞CD25表达为70.2％；受异体角膜激活后，CD4和CD8 T淋巴细胞CD25表达分别为67.3％和52.3％。结论： 异体角膜组织体外能够刺激人外周T细胞CD25表达和T细胞活化，CD4 T细胞比CD8 T细胞活化更明显。     

转染肿瘤总RNA的DC疫苗诱导抗肝癌特异性免疫

目的：探讨转染人肝癌总RNA的树突状细胞(DC) 疫苗体外诱导特异性细胞毒性T淋巴细胞(CTL)的作用。 方法： 采用原发性肝癌（HCC）病人外周血单核细胞（PBMC），在粒/巨细胞集落刺激因子(GM-CSF)和白细胞介素-4(IL-4) 刺激下增殖分化为DC细胞；从人肝癌细胞中体外扩增肝癌RNA。以HCCRNA转染DC细胞，并与PBMC混合培养诱导扩增CTL。MTT法测定CTL的杀瘤活性。 结果： 转染HCCRNA 48 h后， DC表面分子CD83、CD86和HLA-DR表达明显增高。转染HepG-2细胞HCCRNA的DC和病人HCCRNA诱导的CTL对HepG-2细胞和病人HCC细胞的杀瘤活性均明显高于正常肝细胞RNA+DC、脂质体+DC、Opti-MEM+DC以及空白对照组；而对胃癌SGC-7901细胞无杀伤活性。 结论： 以肝癌RNA为肿瘤抗原，DC作为疫苗的抗原提呈细胞，体外冲击致敏DCs，能诱导肝癌特异性CTL。本研究为HCC术后复发和转移的防治提供一种可能有效的疫苗治疗方法。     

严重急性呼吸综合征T细胞亚群Meta分析

目的：研究严重急性呼吸综合症（SAPS）患者T细胞亚群变化。方法：检索2003年2月-2004年1月有关SAPS患者T细胞亚群计数研究的论文，汇合成大样本资料，借助先进的RevMan4．2分析软件对这些资料进行二次分析以探讨该病患者T细胞亚群变化。结果：SAPS病程〈14天期间，患者与正常对照比较，CD3^＋细胞、CD4^＋细胞、CD8^＋细胞均显著降低（均P〈0．01）。其中，重症病人（包括重型和极重型）比非重症病人（包括轻型和普通型）降低更显著（均P〈0．01）。病程〉14天恢复期病人与病程〈14天病人比较，CD3^＋细胞虽然有了上升，但无显著差异（Z=1．56，P=0．12）。CD4^＋细胞、CD8^＋细胞均恢复性上升，差异显著（均P〈0．01）。病程〉14天恢复期病人与正常对照比较，CD3^＋细胞、CD4^＋细胞仍然显著降低（均P〈0．01）。两者的CD8^＋细胞有差异（Z=2．28，P=0．02）。结论：①SAPS患者整个病程中都存在CD3^＋细胞、CD4^＋细胞、CD8^＋细胞数量暂时性、严重性、可逆性降低；②患者T细胞亚群数量的下降以重症病人为甚；③这种降低是可逆性的，随着病程进入恢复期，患者T细胞亚群开始恢复性上升。     

CD4+/CD8+ ratio of liver-derived lymphocytes is related to viraemia and not to hepatitis C virus genotypes in chronic hepatitis C.

The pathogenic mechanisms that lead to chronic hepatitis C are unknown. As hepatitis C virus (HCV) has been shown to induce T cell response, we assessed whether a particular T lymphocyte subset could be preferentially detected in the liver of patients with chronic hepatitis C in relation to viraemia or HCV genotypes. The immunophenotypes of liver-derived lymphocytes were analysed in 26 patients by flow cytometry and immunohistochemistry. Viraemia was quantified by branched DNA assay. Using this assay, HCV RNA was not detectable in six patients. HCV RNA was detected in 20 patients, and titres ranged from 8 to 137 x 10(6) Eq/ml. Genotyping was performed using a line probe assay. Type 1a, 1b, 2a, 3a and 4a were found to infect 2, 10, 2, 7 and 3 patients, respectively. The CD4+/CD8+ ratio of liver-derived lymphocytes was significantly higher (P < 0.01) in patients with detectable viraemia than in patients without detectable viraemia. In contrast, neither the percentage of gamma/delta T lymphocytes nor that of CD2+CD57+ cells was different in the groups. When comparing the CD4+/CD8+ ratio, the percentage of gamma/delta T lymphocytes or CD2+CD57+ cells according to genotype, the differences were not significant. These results suggest that the CD4+/CD8+ ratio of liver-derived lymphocytes is related to viraemia but not to HCV genotypes in patients with chronic hepatitis C, and that T lymphocytes may be involved in the pathogenesis of liver lesions in chronic hepatitis C.     

Loss of mucosal CD4 lymphocytes is an early feature of HIV infection.

T cell subsets in the gut mucosa are distinct populations and their imbalance in HIV has specific implications in infection. Alterations in T cell subsets in duodenal biopsies were investigated in 17 asymptomatic HIV patients, 24 AIDS patients and 10 controls with non-ulcer dyspepsia. Immunohistochemistry and immunofluorescence using MoAbs to CD3, CD4, CD8, CD68, CD45RA, CD45RO and gp120 were performed on frozen sections. In the lamina propria, there was a significant depletion of CD4+ cells at all stages of HIV, but the density of CD8 lamina propria cells was increased. Intraepithelial lymphocytes were decreased in AIDS patients. There was a significant correlation between cellular density and mucosal CD3+ lymphocytes, and between mucosal CD3+ and CD8+ lymphocytes. Although mucosal CD4,CD45RO+ 'memory' cells were decreased, CD8,CD45RO+ 'memory' cells were increased. Mucosal CD4+ lymphocyte depletion occurred early in HIV, and thus their role in mucosal protection against opportunistic infection should be revised. Mucosal CD8+ lymphocytes initially increased, but decreased when CD4 blood counts were depleted, perhaps contributing to loss of host protection against infection. Intraepithelial lymphocyte depletion may also contribute to opportunistic infection.     

Immune Response Induced in Vitro by CD16− and CD16+ Monocyte-Derived Dendritic Cells in Patients with Metastatic Renal Cell Carcinoma Treated with Dendritic Cell Vaccines

Monocyte-derived dendritic cells (mDC) are increasingly used as cancer vaccines. However, human monocytes are a heterogeneous cell population. We showed previously that DC derived from a monocyte subset expressing CD16 (16+mDC) stimulated allogeneic naïve T lymphocytes to secrete higher levels of IL-4 than DC derived from regular CD14^highCD16^? monocytes (16?mDC). Th1-type responses have been associated with effective antitumor responses, thus the use of mDC containing 16+mDC as cancer vaccines might be disadvantageous. Here, we evaluate the primary and memory immune response elicited in vitro by 16+mDC and 16?mDC in five patients with metastatic renal cell carcinoma vaccinated with autologous mDC pulsed with tumor lysates (TuLy) and keyhole limpet hemocyanin (KLH). After therapy, three of the five patients had stable disease. Surprisingly, patients with longer survival showed the highest amount of peripheral blood CD16+ monocytes. Analysis of KLH-specific antibodies revealed high titers of IgG2 in patients with longer survival. CD4+ T lymphocyte proliferation against KLH and TuLy increased after treatment, and some patients showed an augmented rate of CD4+ T lymphocyte proliferation against KLH (3/5) and TuLy (2/3) when 16+mDC were used as antigen presenting cells (APC). Before treatment, the IFN-γ/IL-4 ratio against TuLy and KLH was higher when using 16?mDC as APC, but after vaccination four of five patients had an increased ratio for TuLy with 16+mDC. These results suggest that the immune response elicited by 16?mDC and 16+mDC is modified when memory or naïve T cells are stimulated, and 16+mDC could favor a stronger and more beneficial antitumoral Th1 memory response in vivo.     

肾脏固有细胞和浸润细胞在肾小管间质病变中的作用

Tubulointerstitial lesions,occurring in many kinds of renal diseases,have been found to be the predominant factor in the impairment of renal function.The severe and extensive lesions often predict a poor outcome in future.It has been tested recent years that the infiltrating inflammatory cells might play important roles in the onset and deterioration of tubulointerstitial injuries.On the other hand,the resident cells,including the tubular epithelial cells and the fibroblasts,also directly take part in tubulointerstitial inflammation and fibrosis.Researches also dispaly implicated interactions between the infiltrating cells and the resident cells,which contribute to the amplification of inflammation and the progress of fibrosis.     

Anti-CD2 (OX34) MoAb treatment of adjuvant arthritic rats: attenuation of established arthritis, selective depletion of CD4+ T cells, and CD2 down-modulation

Anti-CD2 MoAbs have previously been shown to induce tolerance and to block B cell differentiation, T cell and monocyte activation. Since these immune functions are important in joint inflammation, we asked whether administration of the anti-CD2 MoAb OX34 has a beneficial effect on established rat adjuvant arthritis, a model of human rheumatoid arthritis, and how it affects CD2-bearing leucocyte subsets. Female Lewis rats with established adjuvant arthritis received a total of 5 mg OX34 or isotype-matched control MoAb starting on day 15 after adjuvant injection. Weight and arthritis score (AS) were measured in a blinded fashion. Peripheral blood cells were analysed for numbers of leucocyte subsets at various time points. Animals were killed on day 30 and lymphatic organs were processed for immunohistology. Clinically, OX34 treatment led to increased body weight and reduced AS. Although OX34 binds to CD4⁺ and CD8⁺ T cells in a comparable fashion, OX34 treatment reduced CD4⁺ T cells, but not CD8⁺ T cells. Among CD4⁺ T cells CD45RC⁺ (‘naive’) T cells virtually disappeared; CD45RC⁻ (‘recently activated’) T cells were slightly reduced. A reduction of CD4⁺ T cells was also found in the lung, liver, bone marrow, spleen and lymph nodes. Down-modulation of the CD2 molecule by OX34, again, affected CD4⁺ T cells, suggesting a specific signal for CD4⁺ but not CD8⁺ T cells. In conclusion, the anti-CD2 MoAb OX34 attenuates established rat adjuvant arthritis. In spite of similar binding to CD4⁺ and CD8⁺ T cells, OX34 depletes only CD4⁺ T cells and down-modulates the CD2 molecule on these cells. These results suggest a therapeutic benefit from CD2-directed therapy for chronic types of arthritis.